United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Lyra Therapeutics raises $30m for chronic rhinosinusitis drug candidates Lyra Therapeutics has raised $30 million in a Series C financing round to advance its lead product candidates… bypharmanewsdailyFebruary 1, 2020
